GLP-1 weight-loss drug, whose full name is Glucagon-like peptide-1 receptor agonist. Initially, GLP-1 was a hormone secreted by the gastrointestinal tract mainly used for treating diabetes, but it has also been used to suppress appetite and control weight.
Baird's optimism is driven by promising developments in Instil’s PD-L1xVEGF bispecific antibody, especially following positive data from peers like Akeso and Summit. Analysts believe this drug class has strong potentia...
FDA Approves Lilly's EBGLYSS™ (lebrikizumab-lbkz) for Adults and Children 12 Years and Older with Moderate-to-Severe Atopic Dermatitis
Will the Sept curse come back to haunt us? Is it fading away? Or there will be a bull party instead? Nothing is for sure. Next week will likely be volatile entering the rate cut week.
Another day of profit from yesterday. Nice.
$Broadcom (AVGO.US)$ $NVIDIA (NVDA.US)$ $Alphabet-A (GOOGL.US)$ $Eli Lilly and Co (LLY.US)$ $Tesla (TSLA.US)$
going
down
again
LLY projected revenue next year is 59B
PFE last year's revenue is already 58B
LLY is close to 1T market value
PFE is 1/6 MV, 165B market value
it's either PFE is extremely undervalued or LLY is ridiculously overvalued!
Some good undervalued stocks are still up for grab. Glad that I have been holding some of them.
It’s hard to time and predict the market, but you can look at the trend for direction. Some good profit from yesterday.
$Alphabet-A (GOOGL.US)$ $Broadcom (AVGO.US)$ $Arm Holdings (ARM.US)$ $NVIDIA (NVDA.US)$ $Novo-Nordisk A/S (NVO.US)$
No comment yet